Sagent Pharmaceuticals,a specialty pharmaceutical company,has launched Ondansetron Injection,USP,an antiemetic,in two latex-free vial presentations.
Ondansetron Injection,USP is indicated for prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy,including high-dose cisplatin,and for prevention of postoperative nausea and/or vomiting.
The injection features the company's PreventIV Measures packaging and labeling,designed to help reduce medication errors.
The US market for Ondansetron Injection,USP for the 12 months ending June 2012 is approximated$49m,according to IMS data.
Source:
http://drugdelivery.pharmaceutical-business-review.com/news/sagent-unveils-ondansetron-injection-usp-120912
